Group One Trading
NRIX icon

Group One Trading’s Nurix Therapeutics NRIX Stock Holding History

Group One Trading’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5K Sell
1,000
-14,400
-94% -$239K ﹤0.01% 6112
2025
Q4 		$292K Sell
15,400
-5,300
-26% -$76.1K ﹤0.01% 4041
2025
Q3 		$191K Buy
20,700
+500
+2% +$5.19K ﹤0.01% 4714
2025
Q2 		$230K Buy
20,200
+18,900
+1,454% +$204K ﹤0.01% 4188
2025
Q1 		$15.4K Sell
1,300
-15,000
-92% -$251K ﹤0.01% 5986
2024
Q4 		$307K Buy
16,300
+14,800
+987% +$339K ﹤0.01% 3568
2024
Q3 		$33.7K Sell
1,500
-3,900
-72% -$88.3K ﹤0.01% 4917
2024
Q2 		$113K Sell
5,400
-2,600
-33% -$40.5K ﹤0.01% 3871
2024
Q1 		$118K Sell
8,000
-16,400
-67% -$176K ﹤0.01% 4022
2023
Q4 		$252K Buy
24,400
+20,300
+495% +$139K ﹤0.01% 3654
2023
Q3 		$32.2K Buy
+4,100
New +$37.4K ﹤0.01% 5481
2022
Q4 		– Sell
-1,300
Closed -$17K – 7820
2022
Q3 		$17K Hold
1,300
– – ﹤0.01% 6182
2022
Q2 		$16K Hold
1,300
– – ﹤0.01% 6460
2022
Q1 		$18K Buy
+1,300
New +$23.1K ﹤0.01% 6823

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Group One Trading's NRIX Position: Q1 2026 in Review

Group One Trading opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 1,456 shares worth $22.6K. The stake represents ﹤0.01% of the portfolio and ranks #5877 among its holdings. This is a return to the name: Group One Trading previously reported a position in NRIX as recently as Q2 2024.

Group One Trading first reported a position in NRIX in Q3 2021 and has held it in 6 quarters since. The position peaked at $45.5K in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Group One Trading held 1,456 shares of Nurix Therapeutics worth $22.6K as of Q1 2026.
  • Nurix Therapeutics was a new Group One Trading position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5877 holding.
  • Group One Trading first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Group One Trading's Nurix Therapeutics position peaked at $45.5K in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.